More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

Amgen announced last week a restructuring plan that would reduce its global workforce by 12% to 15% and close facilities in Washington and Colorado. As Amgen moves forward with this plan, how do its current commercial portfolio and pipeline fare...
DCAT Value Chain Insights

The injectables market has been particularly active this month with three deals announced or closed. A look at the gains in product positions and manufacturing capabilities from recent deals. The injectables market is ramping up with three...
DCAT Value Chain Insights

AbbVie and Shire agree to combine in an approximate $55-billion deal. A look at the management, product positions, and manufacturing capabilities of the proposed combined company. AbbVie and Shire finally came to terms and announced last week an...
DCAT Value Chain Insights

The US Food and Drug Administration (FDA) is receiving mixed signals in its efforts to improve the current Over-the-Counter Monograph Process for reviewing nonprescription drugs. After holding a public hearing earlier this year and opening the...
DCAT Value Chain Insights

As a deadline nears under UK's Takeover Rules, AbbVie and Shire are moving toward common ground in a nearly $54-billion proposal that would combine the two companies. But what would a combined AbbVie and Shire be? DCAT Value Chain Insights examines...
DCAT Value Chain Insights

The US Food and Drug Administration (FDA) issued a draft plan for its strategic priorities through fiscal year (FY) 2018 and highlighted five cross-cutting goals: regulatory science, globalization, safety and quality, smart regulation, and...
DCAT Value Chain Insights

A recent analysis by Battelle and the Biotechnology Industry Organization (BIO), released last week at the BIO International Convention in San Diego, shows continued growth for the US biosciences industry. A study analyzing US bioscience industry...
DCAT Value Chain Insights

The European Investment Bank is teaming with the Belgian biopharmaceutical company UCB in a new model for financing research and innovation projects in the European Union. Research and development (R&D) represent the lifeblood of the...
DCAT Value Chain Insights

The pharmaceutical industry has intensified its new product development efforts in biologics, but has it paid off? A look at the most successful biologic-based drugs launched over the past five years. As the industry gathers this week for the...